All In Biotech

Drug Trial Radar · NCT04493853

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients With DeNovo Metastatic Hormone-Sensitive Prostate Cancer Characterised by PTEN Deficiency.

Last checked: Nov 20, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,012 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,012

Actual

Start

Jul 13, 2020

Primary completion

Oct 7, 2024

Study completion Mar 31, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the combination of capivasertib plus abiraterone (+prednisone/prednisolone) plus ADT is superior to placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC characterised by PTEN deficiency with respect to radiographic progression-free survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Working Group (PCWG3) for bone as assessed by the investigator 2) death due to any cause.

Conditions

  • Hormone-Sensitive Prostate Cancer

Interventions

  • CapivasertibDrug

    400 mg (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • PlaceboOther

    matched to capivasertib appearance (2 tablets) BD given on an intermittent weekly dosing schedule. Patients will be dosed on Days 1 to 4 in each week of a 28-day treatment cycle. Number of Cycles: until disease progression or unacceptable toxicity develops.

  • Abiraterone AcetateDrug

    Administered orally as tablets at a dosage of 1000 mg daily. Administered continuously until criteria for discontinuation are met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic Progression-free Survival (rPFS)Time frame: Tumor assessments every 16 weeks from randomisation until radiographic progression assessed by the investigator. The timing of the Primary analysis DCO for rPFS is approximately 49 months from the first subject randomized

Locations

323 sites in 32 countries. Site status is shown where the registry gives one.

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    La Jolla, California

  • Research Site

    Orange, California

  • Research Site

    San Diego, California

  • Research Site

    Denver, Colorado

  • Research Site

    Lakewood, Colorado

  • Research Site

    Norwich, Connecticut

  • Research Site

    Fort Myers, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Geneva, Illinois

  • Research Site

    Lisle, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Detroit, Michigan

  • Research Site

    Grand Rapids, Michigan

  • Research Site

    Troy, Michigan

  • Research Site

    Syracuse, New York

  • Research Site

    The Bronx, New York

  • Research Site

    Asheville, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Columbus, Ohio

  • Research Site

    Lancaster, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Myrtle Beach, South Carolina

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Houston, Texas

  • Research Site

    Norfolk, Virginia

  • Research Site

    Roanoke, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Berazategui, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    CABA, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

Showing 40 of 323 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.